Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy

  • Authors:
    • María José Serrano
    • Pedro Sánchez Rovira
    • I. Martínez-Zubiaurre
    • Miguel Delgado Rodriguez
    • Mónica Fernández
    • Jose A. Lorente
  • View Affiliations

  • Published online on: April 5, 2012     https://doi.org/10.3892/etm.2012.540
  • Pages: 43-48
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

At present, the majority of patients with breast cancer are diagnosed at early stages of disease development. However, a considerable number of such cases develop secondary malignancies after a relatively short period of time. The presence of circulating tumor cells (CTCs) has been proposed as a strong biomarker to predict disease recurrence in metastatic breast cancer. However, the prognostic significance is not clear in early breast cancer. We present results on CTC determination in peripheral blood in non-metastatic breast cancer patients in the context of neoadjuvant treatment. Twenty-six breast cancer patients, scheduled for neoadjuvant therapy, were enrolled in a prospective study, of which 24 were able to complete therapy. CTC assessment was performed by sorting out cytokeratin-positive cells from 10 ml of peripheral blood using immunomagnetic separation, followed by immunocytochemical characterization of cells. Seventeen blood samples out of 24 patients were CTC-positive when collected prior to neoadjuvant chemotherapy. No significant correlations were found between the presence of CTCs and lymph node status (p=0.1), histological type (p=0.802), stage (p=0.43) or overall survival (OS) (p=0.599). Thirteen CTC-positive samples were observed in blood samples collected after treatment. Univariate analyses revealed that the presence of CTCs was related to OS when the detection was positive both before and after treatment (p=0.023). CTCs can be a strong prognostic marker in early breast cancer. The persistence of CTCs before and after treatment can identify a subpopulation of patients with an increased risk of recurrence.
View Figures
View References

Related Articles

Journal Cover

July 2012
Volume 4 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
José Serrano M, Sánchez Rovira P, Martínez-Zubiaurre I, Delgado Rodriguez M, Fernández M and Lorente JA: Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy. Exp Ther Med 4: 43-48, 2012
APA
José Serrano, M., Sánchez Rovira, P., Martínez-Zubiaurre, I., Delgado Rodriguez, M., Fernández, M., & Lorente, J.A. (2012). Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy. Experimental and Therapeutic Medicine, 4, 43-48. https://doi.org/10.3892/etm.2012.540
MLA
José Serrano, M., Sánchez Rovira, P., Martínez-Zubiaurre, I., Delgado Rodriguez, M., Fernández, M., Lorente, J. A."Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy". Experimental and Therapeutic Medicine 4.1 (2012): 43-48.
Chicago
José Serrano, M., Sánchez Rovira, P., Martínez-Zubiaurre, I., Delgado Rodriguez, M., Fernández, M., Lorente, J. A."Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy". Experimental and Therapeutic Medicine 4, no. 1 (2012): 43-48. https://doi.org/10.3892/etm.2012.540